Taisho Pharmaceutical Co., Ltd.

Rie Nishikawa

Naoya Ono

Tetsuya Yabuuchi

Tetsuo Takayama

Takeshi Koami

Yoshinori Sekiguchi

Hajime Asanuma

Tomomi Ota

Takahiro Oi

Fumiyasu Shiozawa

Yusuke Oka

Shoichi Kuroda

Madoka Kawamura

Fumito Uneuchi

Hironori Katakai

Daisuke Wakasugi

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

The present invention aims to provide compounds which have an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P) and which are useful for pharmaceutical purposes. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: [wherein Ar represents a monocyclic heterocyclic ring containing one or two nitrogen atoms, A represents an oxygen atom or the like, Y, Yand Yeach represent a carbon atom or a nitrogen atom, Rrepresents a hydrogen atom, a C-Calkyl group or the like, Rrepresents a C-Calkyl group, a C-Ccycloalkyl group or the like, Rrepresents a C-Calkyl group or the like, Rrepresents a hydrogen atom or a C-Calkyl group, and Rrepresents a C-Calkyl group or the like].

Binding inhibitor of sphingosine-1-phosphate

Growing community of inventors

Tokyo, Japan

Rie Nishikawa